Xeomin ® | Wave Plastic Surgery & Aesthetic Laser Center
XEOMIN® (incobotulinumtoxinA) for injection, for intramuscular use, is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. XEOMIN® should be administered no more frequently than every three months.
What is XEOMIN®?
XEOMIN® is a prescription medication used in facial aesthetics to temporarily improve the appearance of moderate to severe glabellar frown lines between the eyes (glabellar lines) in adults.
XEOMIN® contains botulinum toxin type A, a protein purified from the bacterium Clostridium botulinum.
XEOMIN® is also sometimes referred to as incobotulinumtoxinA.
XEOMIN® in Aesthetics: How Does it Work?
When you squint or frown, the muscles between your brows contract, causing the skin to furrow and fold. These lines that occur due to facial mimics are referred to as dynamic lines. Over time, as your skin ages and loses some of its elasticity, these repeated contractions can cause persistent frown lines.
Botulinum toxin type A – the active ingredient in XEOMIN® – is used in facial aesthetic treatment to treat dynamic lines like glabellar frown lines. It acts on nerve endings in muscles to prevent muscle fibers from contracting. By reducing these contractions, XEOMIN® can temporarily reduce the frown lines on your forehead between your eyes.
- XEOMIN® is a Botulinum Toxin Type A that blocks transmission of acetylcholine (ACh) from neuron to muscle
- This inhibits muscle contraction and causes muscle paresis (weakness) or paralysis
- Botulinum Toxin Type A only affects "cholinergic neurons" (neurons which use acetylcholine as a neurotransmitter)
- Botulinum Toxin Type A effects dissipate after ~ 3 months because new SNAP-25 proteins take 3 months to be synthesized
Watch XEOMIN® (Botulinum Toxin) in 3D Animation
IS XEOMIN® PROVEN?
XEOMIN® (incobotulinumtoxinA) for injection, for intramuscular use, was proven effective in two randomized, double-blind, multicenter, placebo-controlled clinical trials of more than 540 adult patients in the treatment of glabellar frown lines. The average age of patients in the study was 46 years. Patients received 20 Units of XEOMIN® and were classified as responders if they had a 2-grade improvement on a 4-point scale as assessed by the physician and patient. Using these criteria, treatment success was higher with XEOMIN® than placebo on day 30 in both studies (60% and 48% vs. 0% for placebo in both studies). Based on these trials, XEOMIN® received FDA approval for aesthetic use in 2011.
HOW DO I KNOW IF XEOMIN® IS RIGHT FOR ME?
If you are an adult with moderate to severe glabellar lines (frown lines between the eyes), XEOMIN® may be right for you. Talk to your doctor to discuss the benefits and risks of treatment.
WHAT CAN I EXPECT DURING TREATMENT?
During treatment, which usually takes about 10-20 minutes, your doctor will inject XEOMIN® (incobotulinumtoxinA) for injection, for intramuscular use, into the muscles in your forehead that cause frown lines between your brows. No anesthesia is required; however, your physician may use a topical anesthetic or cold pack to reduce any discomfort.
WHEN CAN I EXPECT TO SEE RESULTS?
In clinical trials, some patients observed visible smoothing as early as 3-4 days after injection. The median first onset of effect was less than a week. The maximum effect occurred at 30 days. The typical duration of effect was up to 3 months in clinical trials but may last significantly longer or shorter in individual patients.
XEOMIN® (incobotulinumtoxinA), for injection, for intramuscular use, is clinically proven to temporarily improve the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.
Using criteria based on combined physician and patient reported response, XEOMIN® was proven to deliver significantly superior efficacy over placebo at day 30 in two randomized, double-blind, multi-center clinical trials.
The studies enrolled 547 healthy patients (≥18 years old) with glabellar lines of at least moderate severity at maximum frown. Three hundred sixty six subjects were treated with 20 Units of XEOMIN® and 181 subjects were treated with placebo. Subjects were excluded if they had marked ptosis, deep dermal scarring, or an inability to lessen glabellar lines, even by physically spreading them apart. XEOMIN® treated subjects ranged from 24 to 74 years of age with a mean age of 46.
Patients were classified as responders only if they had a 2-grade improvement on a 4-point scale compared to baseline as assessed by both the investigator and subject. Using these criteria, the percentage of subjects with treatment success was greater on the XEOMIN® arm than the placebo arm at Day 30 in both studies.
Back to top
Before & After Photos of XEOMIN®
Contact WAVE Cosmetic & Reconstructive Plastic Surgery Center
Offices & Directions to WAVE Plastic Surgery
|LOS ANGELES SURGERY CENTER
|IRVINE AESTHETIC LASER CENTER
|ROWLAND HEIGHTS AESTHETIC LASER CENTER
|LOS ANGELES AESTHETIC LASER CENTER
|FULLERTON AESTHETIC LASER CENTER
View Wave Plastic Surgery & Aesthetic Laser Center in a larger map